Fabinet Logo
Journal Article

Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications

Singh AA,Pooe O,Kwezi L,Lotter-Stark T,Stoychev SH,Alexandra K,Gerber I,Bhiman JN,Vorster J,Pauly M,Zeitlin L,Whaley K,Mach L,Steinkellner H,Morris L,Tsekoa TL,Chikwamba R
Year2020
JournalScientific Reports
Volume10

Abstract

AbstractBroadly neutralising antibodies (bNAbs) against human immunodeficiency virus type 1 (HIV-1), such as CAP256-VRC26 are being developed for HIV prevention and treatment. These Abs carry a unique but crucial post-translational modification (PTM), namelyO-sulfated tyrosine in the heavy chain complementarity determining region (CDR) H3 loop. Several studies have demonstrated that plants are suitable hosts for the generation of highly active anti-HIV-1 antibodies with the potential to engineer PTMs. Here we report the expression and characterisation of CAP256-VRC26 bNAbs with posttranslational modifications (PTM). Two variants, CAP256-VRC26 (08 and 09) were expressed in glycoengineeredNicotiana benthamianaplants. Byin plantaco-expression of tyrosyl protein sulfotransferase 1, we installedO-sulfated tyrosine in CDR H3 of both bNAbs. These exhibited similar structural folding to the mammalian cell produced bNAbs, but non-sulfated versions showed loss of neutralisation breadth and potency. In contrast, tyrosine sulfated versions displayed equivalent neutralising activity to mammalian produced antibodies retaining exceptional potency against some subtype C viruses. Together, the data demonstrate the enormous potential of plant-based systems for multiple posttranslational engineering and production of fully active bNAbs for application in passive immunisation or as an alternative for current HIV/AIDS antiretroviral therapy regimens.